AlphaCentric Advisors’s Insmed INSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.45M Buy
8,874
+1,286
+17% +$198K 1.45% 9
2025
Q4
$1.32M Buy
+7,588
New +$1.38M 1.32% 13
2024
Q4
$271K Sell
3,930
-1,070
-21% -$77.1K 0.27% 94
2024
Q3
$365K Buy
+5,000
New +$369K 0.27% 92
2023
Q4
Sell
-80,000
Closed -$2.02M 261
2023
Q3
$2.02M Sell
80,000
-15,000
-16% -$343K 1.15% 27
2023
Q2
$2M Buy
95,000
+10,500
+12% +$199K 1.11% 24
2023
Q1
$1.44M Buy
84,500
+64,500
+323% +$1.25M 0.99% 26
2022
Q4
$400K Buy
+20,000
New +$387K 0.39% 82
2021
Q4
$776K Hold
28,500
0.23% 44
2021
Q3
$785K Buy
28,500
+4,500
+19% +$118K 0.2% 44
2021
Q2
$683K Buy
24,000
+22,900
+2,082% +$680K 0.19% 42
2021
Q1
$37K Hold
1,100
0.01% 202
2020
Q4
$37K Buy
1,100
+447
+68% +$16.3K 0.02% 194
2020
Q3
$21K Buy
653
+353
+118% +$10.1K 0.01% 145
2020
Q2
$8K Buy
+300
New +$7.11K ﹤0.01% 139

Other funds holding INSM

AlphaCentric Advisors's INSM Position: Q1 2026 in Review

AlphaCentric Advisors increased its Insmed (INSM) stake by 17% in Q1 2026, buying an estimated $198K and bringing the position to 8,874 shares worth $1.45M. The position accounts for 1.45% of the portfolio, ranked #9.

AlphaCentric Advisors first reported a position in INSM in Q2 2020 and has held it in 15 quarters since. The position peaked at $2.02M in Q3 2023. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • AlphaCentric Advisors held 8,874 shares of Insmed worth $1.45M as of Q1 2026.
  • AlphaCentric Advisors bought 1,286 Insmed shares in Q1 2026, an estimated $198K.
  • Insmed made up 1.45% of AlphaCentric Advisors's portfolio in Q1 2026, its #9 holding.
  • AlphaCentric Advisors first reported a position in Insmed in Q2 2020 and has held it in 15 quarters since.
  • AlphaCentric Advisors's Insmed position peaked at $2.02M in Q3 2023.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.